NIKKEI 225
29,098.24 -7.76 (-0.03%) HANG SENG
25,628.74 -409.56 (-1.57%) GOLD FUTURES
1,798.80 +5.40 (+0.30%) DOW
35,490.69 -266.19 (-0.74%) BTC-GBP
42,824.40 -2,705.61 (-5.94%) CMC Crypto 200
1,410.57 -63.76 (-4.32%)
Centessa Pharmaceuticals Limited (CNTA)
After hours: 04:00PM EDT
| Previous close | 16.27 |
| Open | 16.27 |
| Bid | 16.10 x 800 |
| Ask | 20.75 x 2200 |
| Day's range | 15.71 - 16.49 |
| 52-week range | 13.34 - 26.90 |
| Volume | 56,685 |
| Avg. volume | 159,935 |
| Market cap | 1.46B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.67 |
- Business Wire
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
NEW YORK & BOSTON & LONDON, October 18, 2021--Today, Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger announced a collaboration to discover novel orexin receptor agonists.
- Globe Newswire
Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital
~ New $300 million facility, combined with Company’s cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business development opportunities ~BOSTON and LONDON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa” or “Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patie
- Globe Newswire
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for global registrational program ~ ~ Conference call and webcast scheduled for today at 8:30 a.m. EDT ~ CAMBRIDGE, Mass. and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), together with subsidiary ApcinteX Limite
